
麻楠,女,研究员,博士生导师,“广东特支计划”青年拔尖人才。
2011年毕业于中国药科大学,获学士学位;2016年获中国药科大学药物化学博士学位(硕博连读,与中科院广州生物医药与健康研究院联合培养)。同年进入暨南大学开展博士后研究工作;2020年任中国中医科学院青蒿素研究中心副研究员;2021年9月经高层次人才引进加入暨南大学药学院,任研究员。
主要从事药物化学与靶标发现研究,主持国家及省部级科研项目7项,获授权中国发明专利5项;在Lancet,J Am Chem Soc,Angew Chem Int Ed等国际权威期刊发表SCI论文30余篇,多次受邀与诺贝尔奖得主屠呦呦研究员合作发表论文。现兼任中国研究型医院学会神经再生与修复专业委员会委员、iMeta青年编委、Molecules客座编辑及多个SCI期刊审稿人。
讲授课程
1. 本科生课程:《有机化学》、《有机化学实验》、《生物制药导论》
2. 研究生课程:《药学前沿》、《科研论文写作》
研究方向
1. 基于化学蛋白质组学的创新药物靶标识别与鉴定
2. 基于天然生物活性分子的结构修饰
代表性科研项目
1. 国家自然科学基金面上项目(22377036),50万,2024.01-2027.12,主持
2. 国家自然科学基金青年基金项目(81803389),21万,2019.01-2021.12,主持
3. 广东省自然科学基金博士启动--纵向协同项目(2018A030310651),10万,2018.05-2021.04,主持
4. 中国博士后科学基金(2017M622923),5万,2017.03-2018.12,主持
5. 广州市基础与应用基础研究专题(SL2022A04J00501),5万,2023.04 -2025.03,主持
6. 2024年度广东省科协青年科技人才培育计划(SKXRC202416),3万,2024.01-2024.12,主持
7. 中央高校基本科研业务费(21623109),30万,2023.01-2024.12,主持
8. 暨南大学人才引进科研启动经费,100万,2021.09-2027.09,主持
9. 广东省基础与应用基础研究基金自然科学基金-卓越青年团队项目(2024B1515040014),300万,2024.01-2027.12,核心成员
10. 深圳市医学研究专项资金项目(D2403011),300万,2025.01-2027.12,核心成员
代表性论文(近5年)
[1] Ke Cheng, Junyang Qi, Xiaojie Ren, Jie Zhang, Huangxu Li, Hanyue Xiao, Rui Wang, Zhiyang Liu, Lingkuan Meng, Nan Ma*, Hongyan Sun*. Developing Isoxazole as a Native Photo-Cross-Linker for Photoaffinity Labeling and Chemoproteomics. Angew Chem Int Ed Engl, 2022, 21, 61(47). (corresponding author, IF = 16.8)
[2] Nan Ma, Jun Hu, Zhimin Zhang, Wenyan Liu, Minhao Huang, Youlong Fan, Xingfeng Yin, Jiang Wang*, Ke Ding*, Wencai Ye*, Zhengqiu Li*. 2H-Azirine-based Reagents for Chemoselective Bioconjugation at Carboxyl Residues inside Live Cells. J Am Chem Soc, 2020, 142(13): 6051–6059. (IF = 16.3)
[3] Ziyue Zhang#, Wei Huang#, Li Wang#, Guanjun Lia#, Fang Xu , Pengfei Wu , Chuqiao Luo , Qian Huang , Wenhua Kuang , Zhengyong Liu , Ying Jiang , Xiaoling Zhao , Yayuan Zhang*, Wencai Yeb*, Juan Lic*, Nan Ma*, Jigang Wang*. Ailanthone induces triple-negative breast cancer cells death involving the inhibition of OTUB1-mediated ERRα deubiquitylation. J Adv Res, 2025. doi.org/10.1016/j.jare.2025.01.035. (corresponding author, IF = 11.4)
[4] Dandan Liu#, Piao Lu#, Liwei Gu, Qian Zhang, Peng Gao, Yongping Zhu, Xiao Chen, Qiuyan Guo, Junzhe Zhang, Nan Ma*, Jigang Wang*, Celastrol exerts a neuroprotective effect by directly binding to HMGB1 protein in cerebral ischemia-reperfusion. J Neuroinflamm, 2021, 18(1): 1–18. (corresponding author, IF = 10.1)
[5] Nan Ma, Ziyue Zhang, Fulong Liao, Tingliang Jiang, Youyou Tu*. The birth of artemisinin. Pharmacol Ther, 2020, 216: 107658. (IF = 15.7)
[6] Xiao Chen#, Yutong Wang#, Nan Ma#, Jing Tian, Yurou Shao, Bo Zhu, Yin Kwan Wong, Zhen Liang, Chang Zou, Jigang Wang*. Target identification of natural medicine with chemical proteomics approach: probe synthesis, target fishing and protein identification. Signal Transduct Target Ther, 2020, 5(1): 72. (co-first author, IF = 52.7)
[7] Hai-Ning Lyu#, Nan Ma#, Yuqing Meng#, Xing Zhang, Yin-Kwan Wong, Chengchao Xu*, Fulong Liao, Tingliang Jiang, Youyou Tu*, Jigang Wang*. Study towards improving artemisinin-based combination therapies. Nat Prod Rep, 2021, 38(7): 1243-1250. (co-first author, IF = 15.1)
[8] Shengnan Shen#, Qiwen Liao#, Ming Lyu#, Yin-Kwan Wong, Xing Zhang, Jing Zhou*, Nan Ma*, Jigang Wang*. The potential of artemisinins as anti-obesity agents via modulating the immune system. Pharmacol Ther, 2020, 216: 107696. (corresponding author, IF = 15.7)
[9] Yuqing Meng#, Nan Ma#, Hai-Ning Lyu#, Yin Kwan Wong, Xing Zhang, Yongping Zhu, Peng Gao, Peng Sun, Yali Song, Lizhu Lin*, Jigang Wang*. Recent pharmacological advances in the repurposing of artemisinin drugs. Med Res Rev, 2021, 41(6): 3156–3181. (co-first author, IF = 12.3)
[10] Yumei Liao#, Qinghua Zhang#, Qiaoyun Shi#, Peng Liu, Peiyun Zhong, Lingling Guo, Zijian Huang, Yinghui Peng, Wei Liu, Shiqing Zhang, István Adorján, Yumi Fukuzaki, Eri Kawashita, Xiao-Qi Zhang, Nan Ma*, Xiaoshen Zhang*, Zoltán Molnár*, Lei Shi*. Neuroserpin alleviates cerebral ischemia-reperfusion injury by suppressing ischemia-induced endoplasmic reticulum stress. Neural Regen Res, 2024, DOI: 10.4103/NRR.NRR-D-24-00044. (corresponding author, IF = 6.7)
联系方式
邮箱:
![{{siteInfoList.info[5].siteInfo}}](/_upload/tpl/05/36/1334/template1334/images/top_logo.png)